Kintara Therapeutics, Inc. NASDAQ: KTRA
Biotechnology Research
San Diego, California 904 followers
Seeking New Horizons for Cancer Patients
About us
Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001’s indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access
- Website
-
https://www.kintara.com/
External link for Kintara Therapeutics, Inc. NASDAQ: KTRA
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Specialties
- Cancer, Glioblastoma Multiforme, GBM, Ovarian Cancer, Pediatric CNS Tumors, Cutaneous Metastatic Breast Cancer, Recurrent Basal Cell Carcinoma Nevus Syndrome, and Hemodialysis Arteriovenous (AV) Access
Locations
-
Primary
12707 High Bluff Dr
Suite 200
San Diego, California 92130, US
-
3475 Edison Way
Suite R
Menlo Park, California 94025, US
Employees at Kintara Therapeutics, Inc. NASDAQ: KTRA
Updates
-
Today Kintara announced financial results for the 2023 fiscal year and provided a corporate update. Learn more: https://bit.ly/48iTdJa $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
September is #OvarianCancer Awareness Month! Kintara is proud to support the ongoing effort to equip patients with better treatments through our development of REM-001. Get involved via the American Association for Cancer Research: https://bit.ly/3A99AZA Learn more about REM-001: https://bit.ly/3QXWgjA $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
Coverage of Kintara’s KOL event, which featured Dr. Patrick Wen and Dr. James de Groot as presenters, was published in Targeted Oncology. Read about the event and what was presented: https://lnkd.in/eGTWvaJ5 $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
Kintara will present a poster on VAL-083 at #EANO2023 on Saturday, September 23 at 5:15pm CEST. See the details here: https://bit.ly/4611sI0 $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
REM-001 Therapy consists of three parts: a #laser light source, a light delivery device and the drug REM-001. This approach has shown a complete response in approximately 80% of evaluable #tumor sites in previous clinical trials. Learn more about REM-001 Therapy: https://bit.ly/3QXWgjA $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
Thank you to all who attended our KOL event on Monday, and special thanks to our presenters Dr. Patrick Wen and Dr. John de Groot for sharing insights on future of #Glioblastoma treatment. #ICYMI, watch the replay here: https://bit.ly/44gG4wS $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
Kintara Therapeutics KOL Event on VAL-083: A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma - LifeSci Events
-
A reminder that Kintara will host a virtual KOL discussion about the current therapeutic landscape for #Glioblastoma on MONDAY, August 21, at 11:00am ET. A live Q&A session will take place following the presentations by Patrick Y. Wen, M.D. (Harvard Medical School) and John de Groot, M.D. (UCSF Health) See more details and register here: https://bit.ly/44gG4wS $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
Join the Kintara team as we welcome Dr. Patrick Wen and Dr. John de Groot for a virtual KOL event on August 21 at 11:00 AM EDT. The discussion will focus on VAL-083 and the current treatment landscape for #Glioblastoma. Learn more here: https://bit.ly/44gG4wS $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech
-
#ICYMI – CEO Robert E Hoffman shares how the desire to improve patient outcomes motivates Kintara’s work with Jeff Harmon on the Conversations Life Science Leaders Aren't Having #Podcast. Listen: https://bit.ly/3PVaaTn $KTRA #KTRA #Cancer #Oncology #DrugDevelopment #Biotech